TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17882136
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iron and 1 mg riboflavin weekly for 6 months
Study: 17882136
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg zinc and 1 mg riboflavin weekly for 6 months
Study: 17882136
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iron, 20 mg zinc and 1 mg riboflavin weekly for 6 months
Study: 17882136
Drug: Riboflavin alone
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin alone (control) weekly for 6 months
Study: 17245230
Drug: 3-drug efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-drug efavirenz (ZDV/3TC + EFV)
Study: 17245230
Drug: 4-drug efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-drug efavirenz (ZDV/3TC/ABC + EFV)
Study: 11923756
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 microg subcutaneous)
Study: 11923756
Drug: Hydrocortisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (100 mg intravenous)
Study: 9872337
Drug: Clindamycin phosphate/tretinoin
Normalized name: CLINDAMYCIN PHOSPHATE/TRETINOIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin phosphate/tretinoin gel
Study: 9872337
Drug: Clindamycin HCl/tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin HCl/tretinoin gel
Study: 9872337
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate lotion (1% clindamycin; Dalacin T)
Study: 9872337
Drug: Clindamycin phosphate/tretinoin
Normalized name: CLINDAMYCIN PHOSPHATE/TRETINOIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin phosphate/tretinoin gel in acne patients
Study: 7613151
Drug: Allergen injection
Normalized name: catfish allergenic extract
DrugBank: Diphenylpyraline (DB01146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allergen injection immunotherapy
Study: 31008759
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of autologous platelet-rich plasma and fibrin glue (PRP-FG) into the wound after wide excision of the sinus with primary closure
Study: 20627942
Drug: Slow infusion
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow infusion of antithrombin concentrate (100 IU/min) before full-dose heparinisation
Study: 20627942
Drug: Fast infusion
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast infusion of antithrombin concentrate (250 IU/min)
Study: 20627942
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (slow and fast infusion)
Study: 17091331
Drug: High-dose adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adjuvant chemotherapy (mitomycin and tegafur-uracil)
Study: 17091331
Drug: Low-dose adjuvant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adjuvant chemotherapy (mitomycin and tegafur-uracil)
Study: 15602113
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg paroxetine
Study: 12080675
Drug: Xixian tongshuan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xixian tongshuan pill (XTP)
Study: 8614309
Drug: Palmvitee (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palmvitee (40 mg alpha-tocopherol, 48 mg alpha-tocotrienol, 112 mg gamma-tocotrienol, and 60 mg delta-tocotrienol/day for four weeks)
Study: 8614309
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg gamma-tocotrienol/day for four weeks
Study: 8614309
Drug: Tocotrienol preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocotrienol preparations
Study: 8614309
Drug: Neither preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither preparation
Study: 2076798
Drug: Subcutaneous glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous glucagon (1 mg)
Study: 2076798
Drug: Glycocholic acid
Normalized name: Glycocholic acid
DrugBank: Glycocholic acid (DB02691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycocholic acid (1 mg)
Study: 7039058
Drug: Gentamicin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1 mg/kg/iv q8h)
Study: 7039058
Drug: Tobramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1 mg/kg/iv q8h)
Study: 30328105
Drug: Paroxetine (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (selective serotonin reuptake inhibitor)
Study: 28655183
Drug: Internet-delivered therapist-guided
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered therapist-guided cognitive behavior therapy for insomnia
Study: 28655183
Drug: Internet-delivered therapist-guided
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered therapist-guided cognitive behavior therapy for depression
Study: 24332687
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with cocaine 4% pledgets
Study: 24332687
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with lidocaine 2% plus 1/100.000 adrenaline pledgets
Study: 22849337
Drug: Carvedilol 6.25‐12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 6.25‐12.5 mg daily
Study: 22849337
Drug: Nadolol 40‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 40‐80 mg plus isosorbide‐5‐mononitrate 20 mg daily
Study: 19726349
Drug: Parenteral plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral plus enteral nutrition (PN+EN)
Study: 16301340
Drug: Thalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (25 mg QD increasing to 200 mg QD)
Study: 9456273
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate 120 mg sustained-release once daily
Study: 9456273
Drug: Molsidomine 8
Normalized name: molsidomine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsidomine 8 mg sustained-release 3 times daily
Study: 2146996
Drug: Infusions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions of third-party donor leucocytes
Study: 30014671
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of parecoxib sodium (40 mg), combined with regular anesthesia
Study: 30014671
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of dezocine (5 mg), combined with regular anesthesia
Study: 17623736
Drug: IVIG 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 0.4 g/kg per month
Study: 16220024
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (prior to antidepressive treatment)
Study: 9923795
Drug: Exogenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exogenous insulin (n = 8)
Study: 2103755
Drug: Micronutrient antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient antioxidant therapy (daily doses of 600 micrograms organic selenium, 9000 IU beta carotene, 0.54 g vitamin C, 270 IU vitamin E, and 2 g methionine)
Study: 29490041
Drug: Solution-focused wellness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused wellness intervention (seven-week duration)
Study: 24582799
Drug: Calcium lactate
Normalized name: Calcium Lactate
DrugBank: Calcium lactate (DB13231)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium lactate pre-rinse (CaL, 150mmol/L, 1min) followed by fluoride rinse (NaF 12mmol/L, 1min)
Study: 24582799
Drug: Fluoride rinse
Normalized name: ACT Fluoride Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride rinse only (NaF 12mmol/L, 1min)
Study: 22257577
Drug: NVA237 (glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 (glycopyrronium bromide) at doses of 25, 50, 100, or 200 μg
Study: 8707580
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream corresponding to Optiderm
Study: 6197081
Drug: Radiotherapy to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy to the primary site followed by 10 pulses of chemotherapy (cyclophosphamide, methotrexate, CCNU)
Study: 6197081
Drug: Two pulses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two pulses of chemotherapy (cyclophosphamide, methotrexate, CCNU) followed by radiotherapy and then 8 pulses of chemotherapy
Study: 22810146
Drug: CMV serostatus
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV serostatus (measured by CMV IgG antibodies)
Study: 20216555
Drug: Active FM
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active FM (fermented milk containing Lactobacillus gasseri SBT2055), n=43, 200 g/day for 12 weeks
Study: 20216555
Drug: Control FM
Normalized name: FM-VP4
DrugBank: FM-VP4 (DB05449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control FM (fermented milk without Lactobacillus gasseri SBT2055), n=44, 200 g/day for 12 weeks
Study: 17505679
Drug: Active TEA
Normalized name: IODINE 100 g in 100 g TOPICAL CREAM [Active Teat Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TEA (15 ml 0.5% bupivacaine)
Study: 17505679
Drug: Placebo (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (15 ml 0.9% saline)
Study: 8533119
Drug: Phenytoin 100
Normalized name: phenytoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin 100 mg/day, 200 mg/day, or 300 mg/day for 14 weeks
Study: 31283908
Drug: nabilone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabilone (0.5 mg)
Study: 31283908
Drug: nicotine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicotine (6 mg)
Study: 31283908
Drug: nicotine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: nicotine (6 mg) + nabilone (0.5 mg)
Study: 23004922
Drug: Low-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ASA (100 mg/d) ingested 8 hours after awakening
Study: 23004922
Drug: Low-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ASA (100 mg/d) ingested at bedtime
Study: 23004922
Drug: Low-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ASA (100 mg/d) ingested upon awakening
Study: 23004922
Drug: Low-dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose ASA (100 mg/d)
Study: 10929272
Drug: Corticosteroids or
Normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids or adrenocorticotropic hormone (ACTH) treatment
Study: 10929272
Drug: Corticosteroids or
Normalized name: Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids or ACTH treatment
Study: 1344236
Drug: Intramuscular meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine 25mg IM
Study: 6424464
Drug: Oral nonabsorbable
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nonabsorbable antibiotics and isolation in laminar airflow room (36 patients)
Study: 6424464
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment in single rooms with hand-washing and mask precautions (31 patients)
Study: 15547093
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment (5 mg/kg)
Study: 9747153
Drug: rt-PA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (20 mg administered locoregionally over 4 hours for a maximum of 7 days)
Study: 9747153
Drug: urokinase (100,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: urokinase (100,000 IU/h administered locoregionally for a maximum of 7 days)
Study: 9747153
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous heparin infusions after PTT)
Study: 2467608
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (ST) - penicillin-chloramphenicol combination with or without sulphadiazine
Study: 31586206
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) during maintenance chemotherapy (Group 1)
Study: 31586206
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) at end of chemotherapy (Group 2)
Study: 31586206
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV13) 6 months after chemotherapy (Group 3)
Study: 28292331
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for depression, 16-20 sessions
Study: 26430087
Drug: Increased urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urinary excretion of urea nitrogen (≥ 8 g/d)
Study: 16862612
Drug: TEP laparoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEP laparoscopic patch repair
Study: 10165553
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement patch (Prostep, Lederle Laboratories) with no additional support (Group I, n = 166)
Study: 10165553
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement patch (Prostep, Lederle Laboratories) with 24-hour telephone hotline support (Group II, n = 167)
Study: 10165553
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement patch (Prostep, Lederle Laboratories) with 24-hour telephone hotline support and four follow-up calls (Group III, n = 167)
Study: 8475816
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg fusidic acid (intervention)
Study: 3823635
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of prednisolone
Study: 30661105
Drug: CBD alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD alone (400 mg)
Study: 30661105
Drug: THC alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC alone (8 mg)
Study: 30661105
Drug: THC combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC combined with low dose CBD (4 mg)
Study: 30661105
Drug: THC combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC combined with high dose CBD (400 mg)
Study: 29110150
Drug: 30-min, vigorous-intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-min, vigorous-intensity treadmill bout 24 hours prior to each of four doxorubicin treatments
Study: 19226891
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and conventional rehabilitation therapy
Study: 19226891
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapy (Control)
Study: 10232685
Drug: Continued ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued ramipril (1.25 to 5 mg/d)
Study: 6287359
Drug: Physostigmine (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine (single IV infusion)
Study: 23639793
Drug: Antipsychotic trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic trials with adequate allocation concealment, double blinding, higher precision, larger trial size, at least three treatment arms, recent publication, conducted in the United States, and enrollment of inpatients
Study: 21317283
Drug: Tolvaptan 15
Normalized name: tolvaptan 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 15 mg daily (titrated to 30 and 60 mg if necessary)
Study: 16934685
Drug: Oltipraz 125
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 125 mg daily
Study: 16934685
Drug: Oltipraz 500
Normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oltipraz 500 mg weekly
Study: 9457093
Drug: Early amniocentesis
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early amniocentesis (11 mL, between 11(+0) and 12(+6) gestational weeks)
Study: 9457093
Drug: Midtrimester amniocentesis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midtrimester amniocentesis (20 mL, between 15(+0) and 16(+6) gestational weeks)
Study: 8572639
Drug: Treatment A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: 1 mg of GRAN initially and 12 hours after the first dose
Study: 8572639
Drug: Treatment B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: a single 2 mg dose of GRAN
Study: 1023957
Drug: Doxapram 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxapram 250 mg in dextrose 5%
Study: 20849938
Drug: BGP-15 (400mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGP-15 (400mg once daily for 17 days)
Study: 18179312
Drug: Visually-impoverished environment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually-impoverished environment training under alcohol (0.65 g/kg)
Study: 18179312
Drug: Normal visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal visual environment training under alcohol (0.65 g/kg)
Study: 10682110
Drug: GDP-free PD
Normalized name: Poly Hist PD
DrugBank: Thonzylamine (DB11235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDP-free PD solution
Study: 24711637
Drug: Conventional PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional PD solution
Study: 2283647
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg (10 patients) and 20 mg (2 patients) twice daily for 8 weeks
Study: 23896377
Drug: Adjuvant PCV
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant PCV (Procarbazine, CCNU, Vincristine) chemotherapy
Study: 15151167
Drug: Acetaminophen (1g)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1g) administered after zobo drink
Study: 15151167
Drug: Acetaminophen (1g)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1g) administered alone
Study: 9832115
Drug: High-dose lisinopril-isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lisinopril-isosorbide dinitrate therapy
Study: 9832115
Drug: Established doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established doses of angiotensin-converting enzyme inhibitor and nitrate therapy
Study: 2561096
Drug: Oral Glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Glucose Tolerance Test (O‐GTT)
Study: 2561096
Drug: Insulin Secretion
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Secretion Test (IST)
Study: 31984598
Drug: Tirzepatide 12
Normalized name: tirzepatide 12.5 MG in 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 12 mg
Study: 31984598
Drug: Tirzepatide 15
Normalized name: tirzepatide 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 15 mg-1
Study: 31984598
Drug: Tirzepatide 15
Normalized name: tirzepatide 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide 15 mg-2
Study: 23262999
Drug: GS-9851 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: GS-9851 (25 to 800 mg)
Study: 21636183
Drug: Oral essential
Normalized name: Eucalyptus essential oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral essential amino acids 4 gr 2 times a day for 8 weeks
Study: 18175066
Drug: E+L+ (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: E+L+ (10 + 50 mg/day)
Study: 18175066
Drug: L+ (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L+ (50 mg/day)
Study: 17205814
Drug: Shenle Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenle Capsule (SC)
Study: 14638484
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg)
Study: 9046509
Drug: Traditional non-operative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional non-operative therapy
Study: 1951149
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement given twice a day providing an average of 10.66 kJ (400 kcal) and 5 g protein/d.
Study: 1951149
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dietary supplement).
Study: 26247967
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid supplementation (EPA + DHA) at varying doses (Study 1: 0, 300, 600, 900, and 1800 mg/day; Study 2: 0, 850, and 3400 mg/day)
Study: 17611715
Drug: Paclitaxel alone
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel alone (total cumulative dose range: 950‐2,475 mg/m2)
Study: 17611715
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and adriamycin (total cumulative dose range: 700‐2,800 mg/m2)